In late November, the Sputnik V developers also offered foreign vaccine producers their help
The facility is part of COVAX, a coalition of governments, health organisations, businesses and charities working to accelerate the development of Covid-19 vaccines
PARIS (Reuters) - French drugmaker Sanofi and its British peer GSK have started a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical companies race to develop treatments
A Sanofi executive said the companies had not yet agreed with the US on a specific price for additional doses
Glaxo shares traded 1.6 per cent higher in London, with Sanofi up 1.4 per cent in Paris
The company said it still expects adjusted earnings per share for the year to decline in the range of 1% to 4%
GSK and CureVac, backed by Bill Gates, will work on developing up to five so-called mRNA-based vaccines and monoclonal antibodies (mAbs) for infectious diseases, they said.
GSK, which is in seven collaborations with institutions or firms globally, only entered the clinical trial stage with one project on Friday
The British drugmaker is working on its own COVID vaccine with Sanofi
April sales were the worst among top drug players
The performance of banking stocks is likely to weigh on the markets
Hindustan Unilever will be in focus today as UK-based GSK will offload shares worth Rs 26,000 crore in the FMGC major
New launches stagnate as fresh prescriptions dry up
The firm's operating revenue stood at Rs 1,159 crore - up 3.7 per cent YoY from Rs 1,117 crore
Albert Bourla, CEO of Pfizer, discussed the time frame for the IPO at the JPMorgan Healthcare Conference in San Francisco on Tuesday
Repositioning an old brand helps expand the footprint, say analysts
STEER which was founded in 1993 by Padmanabhan has 5 global offices and 10 satellite offices, serving over 39 countries. It employs over 500 engineers, scientists and technicians across the globe
More price increases are expected to be announced later this week, which could affect the median and range.
Indian companies have also been hit in their global business.
If approved by regulators, the medicine will be the first new generation HIV medicine available in baby-friendly form